Open Access

Targeting transient receptor potential canonical 1 reduces non‑small cell lung cancer chemoresistance and stemness via inhibition of PI3K/AKT signaling

  • Authors:
    • Jiahui Jin
    • Xinyu Yan
    • Yaru Zhao
    • Haojie Zhang
    • Kai Zhuang
    • Yating Wen
    • Jingjing He
    • Junzhen Gao
  • View Affiliations

  • Published online on: April 13, 2023     https://doi.org/10.3892/ol.2023.13810
  • Article Number: 224
  • Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

TRPC1 enhances cell proliferation and migration in non‑small cell lung cancer (NSCLC); however, its effect on NSCLC chemoresistance and stemness remains to be determined. The aim of the current study was to investigate the effect of TRPC1 on NSCLC chemoresistance and stemness and to determine the underlying mechanism of action. Cisplatin‑resistant A549 (A549/CDDP) and H460 (H460/CDDP) cells were first established and were then transfected with negative control small interfering (si)RNA (si‑NC) or TRPC1 siRNA (si‑TRPC1). Cells were then treated with 740 Y‑P, a PI3K/Akt agonist. Subsequently, the sensitivity of A549/CDDP and H460/CDDP cells to CDDP was evaluated. Furthermore, the expression levels of CD133 and CD44, and sphere formation ability were also determined. The results showed that the half‑maximal inhibitory concentration (IC50) of CDDP was significantly higher in A549/CDDP cells compared with A549 cells and in H460/CDDP cells compared with H460 cells. TRPC1 silencing decreased the IC50 value of CDDP compared with the si‑NC group in A549/CDDP (11.78 vs. 21.58 µM; P<0.01) and H460/CDDP (23.76 vs. 43.11 µM; P<0.05) cells. Additionally, TRPC1 knockdown in both cell lines decreased the number of spheres formed compared with the si‑NC group. Furthermore, compared with the si‑NC group, A549/CDDP cells transfected with si‑TRPC1 exhibited decreased levels of both CD133 (P<0.01) and CD44 (P<0.05). However, only CD133 (P<0.05) was downregulated in TRPC1‑depleted H460/CDDP cells compared with the si‑NC group. In addition, TRPC1 knockdown repressed PI3K/AKT signaling compared with the si‑NC group in both A549/CDDP and H460/CDDP cells (all P<0.05). Finally, cell treatment with 740 Y‑P reversed the effect of TRPC1 knockdown on PI3K/AKT signaling, chemoresistance, and cancer stemness in A549/CDDP and H460/CDDP cells (all P<0.05). In conclusion, the results of the current study suggested that targeting TRPC1 could attenuate cancer stemness and chemoresistance via suppression of PI3K/AKT signaling in NSCLC.
View Figures
View References

Related Articles

Journal Cover

June-2023
Volume 25 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jin J, Yan X, Zhao Y, Zhang H, Zhuang K, Wen Y, He J and Gao J: Targeting transient receptor potential canonical 1 reduces non‑small cell lung cancer chemoresistance and stemness via inhibition of PI3K/AKT signaling. Oncol Lett 25: 224, 2023.
APA
Jin, J., Yan, X., Zhao, Y., Zhang, H., Zhuang, K., Wen, Y. ... Gao, J. (2023). Targeting transient receptor potential canonical 1 reduces non‑small cell lung cancer chemoresistance and stemness via inhibition of PI3K/AKT signaling. Oncology Letters, 25, 224. https://doi.org/10.3892/ol.2023.13810
MLA
Jin, J., Yan, X., Zhao, Y., Zhang, H., Zhuang, K., Wen, Y., He, J., Gao, J."Targeting transient receptor potential canonical 1 reduces non‑small cell lung cancer chemoresistance and stemness via inhibition of PI3K/AKT signaling". Oncology Letters 25.6 (2023): 224.
Chicago
Jin, J., Yan, X., Zhao, Y., Zhang, H., Zhuang, K., Wen, Y., He, J., Gao, J."Targeting transient receptor potential canonical 1 reduces non‑small cell lung cancer chemoresistance and stemness via inhibition of PI3K/AKT signaling". Oncology Letters 25, no. 6 (2023): 224. https://doi.org/10.3892/ol.2023.13810